Acta clinica Croatica, Vol. 49 No. 4, 2010.
Other
Recurrent Venous Thrombosis Despite ‘Optimal Anticoagulation Therapy’ for Antiphospholipid Syndrome – Could New Oral Anticoagulants Solve the Problem?
Manuela Balaban
Vladimir Stančić
orcid.org/0000-0003-1607-2992
Goran Rinčić
Mario Ledinsky
Nada Lang
Ljiljana Grbac
Nevenka Stančić
Hrvoje Tomašić
Abstract
The aim was to determine the validity of the international normalized ratio (IN R) and prothrombin time (PT ) as a monitor for warfarin therapy in patients with lupus anticoagulants and recurrent thrombosis, and to investigate alternative approaches to monitoring warfarin therapy and new treatment options in these patients. A case is described of a 63-year-old female with antiphospholipid syndrome and recurrent venous thrombosis despite optimal adjusted warfarin therapy. In patients with lupus anticoagulants, the IN Rs obtained while receiving warfarin vary and often overestimate the extent of anticoagulation, while PT without receiving warfarin is often prolonged. In conclusion, lupus anticoagulants can influence PT and lead to IN R that does not accurately reflect the true level of anticoagulation. Optimizing of (warfarin) oral anticoagulation therapy could be achieved by individual monitoring of anticoagulation effect with a test that is insensitive to lupus anticoagulants (chromogenic factor X assay). Emerging oral anticoagulants, direct thrombin inhibitors and direct factor Xa inhibitors, such as dabigatran and rivaroxaban, with a predictable anticoagulant response and little potential for food or drug interactions, have been designed to be administered in fixed doses without coagulation monitoring and could be the treatment choice for these patients.
Keywords
Antiphospholipid syndrome – complications; Antiphospholipid syndrome – drug therapy; Thrombosis – etiology; Thrombosis – prevention and control; Warfarin – therapeutic use; Case report
Hrčak ID:
84807
URI
Publication date:
20.12.2010.
Visits: 2.978 *